Tumor Microenvironment and Progression to Invasion after a Diagnosis of Ductal Carcinoma In Situ

Abstract

Ductal carcinoma in situ (DCIS) makes up 18% of all new breast cancer diagnoses, and is considered a precursor to invasive breast cancer even though the majority of cases almost 70% may never progress to invasive disease. Markers that identify which patients are most likely to experience progression are critically needed so that fewer patients are over-treated. This study is evaluating two novel tumor markers that may indicate greater risk of tumor progression based on recent work that suggests that stromal syndecan-1 expression induces an extracellular matrix with aligned collagen fiber architecture, and that this collagen alignment in turn facilitates malignant cell invasion. We are using archived tumor tissue from 267 cases of DCIS of the breast to evaluate syndecan-1 expression and collagen alignment. These DCIS cases, diagnosed between 1995 and 1999, have been followed for breast cancer outcomes; 13% of cases have experienced a second breast cancer diagnosis. Analysis suggests that treatment and method of detection are important covariates to include in statistical modeling. Preliminary analysis of collagen alignment and syndecan-1 expression suggests that features of the tumor microenvironment are related with disease-free survival after a diagnosis of DCIS.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Nov 01, 2013
Accession Number
ADA592134

Entities

People

  • Amy Trentham-dietz
  • Patricia Keely

Organizations

  • University of Wisconsin–Madison

Tags

DTIC Thesaurus Topics

  • Breast Cancer
  • Carcinoma
  • Colon Cancer
  • Data Analysis
  • Data Science
  • Demographic Cohorts
  • Detection
  • Diseases And Disorders
  • Health Services
  • Information Science
  • Institutional Review Board
  • Medical Personnel
  • Monte Carlo Method
  • Neoplasms
  • Statistical Analysis
  • Surgery
  • Surveys

Readers

  • Oncology (Cancer Research).
  • Oncology and Biomarker-Based Cancer Detection.
  • Trauma Surgery or Emergency Medicine.